Riskpilot← Back to searchSign inGet full accessReaGenix AB
ABActiveOrg 5593751844Hälsovägen 7Wholesale of chemical products · NACE 4685Est. 20221 employees
Revenue 2024
SEK -2
-100% vs 2023
EBITDA margin
2253850.0%
-264% vs 2023
Equity ratio
100.0%
Financial strength
Net profit 2024
SEK -48K
-140% vs 2023
| Revenue | SEK -2 | -100% |
| EBITDA | SEK -45K | -264% |
| Net profit | SEK -48K | -140% |
| Total assets | SEK 38K | -62% |
| Equity | SEK 38K | -56% |
| Employees | 1 | — |
Legal name
ReaGenix AB
Org number
5593751844
Legal form
Aktiebolag
NACE code
4685 · Wholesale of chemical products
Founded
8 april 2022
Share capital
SEK 25 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av Bannikau, Vadzim Tuzin, Uladzimir
Company purpose
Bolaget skall direkt eller indirekt via dotterbolag bedriva konsulterande verksamhet inom etablering, affärsutveckling, utveckling av fastigheter och stadskärnor, rådgivning i samband med fastighetsinvesteringar, samt eget deltagande som delägare eller finansiär av fastighetsprojekt eller därmed förenlig verksamhet. Näringsgren Konsultverksamhet avseende företagsorganisation
Address
Hälsovägen 7
Email
info@reagenixab.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | 375 | 115 | −0 |
| Staff expenses | — | −64 | −5 |
| EBITDA | 80 | −12 | −45 |
| Depreciation & amort. | −0 | — | — |
| EBIT | 80 | −12 | −45 |
| Net financials | — | −7 | −3 |
| Profit before tax | 80 | −20 | −48 |
| Tax | −0 | — | — |
| Net profit | 80 | −20 | −48 |
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Total assets | 206 | 99 | 38 |
| Equity | 105 | 85 | 38 |
| Long-term debt | 0 | — | — |
| Short-term debt | 101 | 14 | 0 |
| Total debt | 101 | 14 | — |
EBITDA margin
-4507700.0%
This company
15.8%
Market median
-28529847% vs market
20222024
Equity ratio
100.0%
This company
38.2%
Market median
+162% vs market
20222024
Return on equity
-126.2%
This company
18.4%
Market median
-786% vs market
20222024
Net profit margin
-4758700.0%
This company
8.1%
Market median
-58749483% vs market
20222024
Asset turnover
-0.00×
This company
1.12×
Market median
-100% vs market
20222024
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20222024
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
VB Chief Executive Officer | Chief Executive Officer | 2026 |
| Former (1) | ||
SA Chief Executive Officer | Chief Executive Officer | 2025 – 2026 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2026 | |
| Board of Directors | 2026 | |
| Former (2) | ||
| Chairman | 2025 – 2026 | |
| Deputy Board Member | 2022 – 2026 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of ReaGenix AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Vadzim Bannikau | Chief Executive Officer | 0 companies |
| Sarkis Arturovitj Safarian | Chief Executive Officer | 0 companies |
| Ina Bannikava | Deputy Board Member | 0 companies |
| Uladzimir Tuzin | Board of Directors | 0 companies |
| Karen Safarian | Chairman | 0 companies |
| Karine Yegorian | Deputy Board Member | 0 companies |